EC Number |
Protein Variants |
Reference |
---|
2.7.1.137 | C838C/I848A |
site-directed mutagenesis, 10% activity compared to the wild-type enzyme |
661328 |
2.7.1.137 | C838I/I848A |
site-directed mutagenesis, below 10% activity compared to the wild-type enzyme |
661328 |
2.7.1.137 | C838L/I848A |
site-directed mutagenesis, highly reduced activity, 0.1% compared to the wild-type enzyme |
661328 |
2.7.1.137 | D2243E |
site-directed mutagenesis, no functional complementation of a yeast enzyme-knockout mutant strain |
661328 |
2.7.1.137 | D743N |
kinase-dead catalytic loop mutant |
722120 |
2.7.1.137 | D749E |
site-directed mutagenesis, no functional complementation of a yeast enzyme-knockout mutant strain |
661328 |
2.7.1.137 | E545K |
a dominant activating mutation of the catalytic subunit PIK3CA that is prevalent in breast cancer and confers resistance to lapatinib, lapatinib effectively inhibits the transactivation of EGFR and HER2 by IGF-I signaling |
707976 |
2.7.1.137 | G373R |
naturally occuring mutation in gene PIK3R2 involved in bilateral perisylvian polymicrogyria |
738948 |
2.7.1.137 | H1047R |
a dominant activating mutation of the catalytic subunit PIK3CA that is prevalent in breast cancer and confers resistance to lapatinib, lapatinib effectively inhibits the transactivation of EGFR and HER2 by IGF-I signaling |
707976 |
2.7.1.137 | H1047R |
HCT-116 cells are heterozygous for gain of function mutant PIK3CA catalytic subunit |
709003 |